Verkorting van de therapieduur bij patiënten met longtuberculose van 9 naar 6 maanden verdedigbaar op grond van gepubliceerde gegevens
Open

Onderzoek
03-11-1996
J.H. van Loenhout-Rooyackers, J. Veen en A.L.M. Verbeek

Shortening of the duration of treatment in patients with pulmonary tuberculosis from 9 to 6 months justifiable on the basis of literature data.

To determine if in the Netherlands, just like in other countries, the treatment of pulmonary tuberculosis with adequately sensitive tubercle bacilli may be shortened from 9 to 6 months.

Design.

Literature study.

Setting.

Municipal Health Service, Nijmegen, the Netherlands.

Method.

The relevant literature was analysed, using the percentage of recurrences as the criterion. The study was restricted to patients with pulmonary tuberculosis in whom the diagnosis had been confirmed bacteriologically and in whom a human, normally sensitive tubercle bacillus had been isolated. The treatment schedule had to include at least isoniazod, rifampicin and pyrazinamide. There were no studies with treatment of 9 months‘ duration. The studies with 6 months’ treatment were selected on the basis of the predetermined criteria from among articles included in Medline in 1980-1991.

Results.

The treatment schedules of 6 months‘ duration (n = 44) from 25 articles were suitable for analysis. Treatment for 6 months’ resulted in a proportion of recurrences of tuberculosis of 2.4 (95-confidence interval: 2.0-2.8), with follow-up periods of 12 to 94 months after discontinuation of the treatment. Addition of streptomycin or ethambutol during the initial phase, self-medication or controlled treatment, daily or intermittent treatment made no difference as regards the ultimate results. No comparison with the proportion of recurrences of 1 (0.2-2.9) after 9 month's treatment without pyranizamide was possible. A recent calculation of the number of Dutch nationals with recurrent tuberculosis resulted in a proportion of recurrences of 2.5 (1.8-3.2). The guideline adopted was that mentioned by the American Thoracic Society, a proportion of recurrences of < 5.

Conclusion.

On the basis of the known percentages of recurrence, it could be decided in the Netherlands as well to shorten the duration of treatment from 9 to 6 months.